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ABSTRACT 23 
Caucasian population groups have a higher propensity to develop skin cancer, and associated 24 
clinical interventions often present substantial financial burden on healthcare services. 25 
Conventional treatments are often not suitable for all patient groups as a result of poor 26 
efficacy and toxicity profiles. The primary objective of this study was to develop a 27 
deformable liposomal formulation, the properties of which being dictated by the surfactant 28 
Tween 20, for the dermal cellular delivery of epigallocatechin gallatein (EGCG), a compound 29 
possessing antineoplastic properties. The results demonstrated a significant (p ≤0.05) 30 
decrease in liposome deformability index (74 ± 8 to 37 ± 7) as Tween 20 loading increased 31 
from 0 to 10 % w/w, indicating an increase in elasticity. EGCG release over 24-hours 32 
demonstrated Tween 20 incorporation directly increased release from 13.7 % ± 1.1 % to 94.4 33 
% ± 4.9 % (for 0 and 10 % w/w Tween 20 respectively). Finally, we demonstrated DilC-34 
loaded deformable liposomes were localised intracellularly within human dermal fibroblast 35 
and keratinocyte cells within 2-hours. Thus it was evident deformable liposomes may aid 36 
drug penetration into dermal cells and would be useful in developing a controlled-release 37 
formulation. 38 
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1. Introduction 46 
Skin cancer is an increasing public health problem particularly in developed countries 47 
[1].  Currently, 2-3 million non-melanoma skin cancers and 132,000 melanoma skin cancers 48 
occur globally each year [2]. The large number of cases diagnosed present as a substantial 49 
burden to healthcare services [3, 4, 2]. Despite the fact that the majority of skin cancers are 50 
treatable, malignant forms of the cancer results in over 9,000 deaths annually worldwide [5]. 51 
Current treatment approaches are limited to local surgery to remove the tumour in addition to 52 
topical treatments with cream formulations.  However, surgical removal may not be suitable 53 
for all patients whilst topical therapies are often linked with poor patient compliance 54 
stemming from high dose frequency requirements and unpleasant side effects [6]. In addition, 55 
topical treatments may cause skin irritation, weeping, cracking and blistering causing 56 
discomfort and pain [7-9].  57 
Strategies for cancer management are focused on chemoprevention and 58 
chemoprotection. Existing anticancer agents often demonstrate poor safety profiles in 59 
addition to unpleasant side effect profiles, and there is an urgent need for novel agents which 60 
are both efficacious and possess a limited toxicity profile to non-malignant dermal tissue [10-61 
12]. One group of compounds that have gained interest recently as novel candidates for this 62 
purpose are flavonoids, naturally occurring chemicals abundantly expressed in food and drink, 63 
and in particular the green tea catechin, epigallocatechin gallatein (EGCG) which is 64 
increasingly being exploited for its chemoprevention properties [13-15]. EGCG has been 65 
found to affect specific biological processes that could be exploited as targets for the 66 
prevention and treatment of cancer [16], and has been demonstrated to possess properties 67 
associated with the induction of apoptosis [17], promotion of cell growth arrest by altering 68 
the expression of cell cycle regulatory proteins [17], activation of killer caspases and the 69 
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suppression of oncogenic transcription factors [18, 19, 15] and pluripotency maintaining 70 
factors [20].  However, the application of naturally occurring compounds as 71 
chemopreventative and chemoprotective strategies for skin cancer management has so far 72 
been received with limited success and this may be largely due to inefficient delivery systems 73 
and limited oral bioavailability of promising agents [21-23]. Consequently, to achieve 74 
maximum clinical efficacy, novel approaches are required to enhance compound 75 
bioavailability, of which dermal delivery is particularly promising.  76 
The principle function of mammalian skin is to offer protection from environmental 77 
chemicals and xenobiotics [24].  The penetration of drugs across the skin is significantly 78 
inhibited by the skin’s inherent barrier properties [25] thus there is a need to develop carrier 79 
systems to enhance penetrability. To fulfil this goal, when applied topically nanoparticle 80 
mediated delivery systems (e.g. microemulsions, liposomes, ethosomes, deformable 81 
liposomes and solid lipid nanoparticles), would benefit the direct dermal delivery of 82 
compounds across the stratum corneum [26-28]. Additionally, such nano-scale structures are 83 
capable of improving drug loading, enhancing systemic bioavailability, imparting a sustained 84 
release profile and allowing targeted drug delivery [29, 30]. Furthermore, the topical 85 
application of such carriers reduces the incidence of undesirable side effects arising from 86 
systemic administration and enhances systemic absorption of drugs after topical application 87 
with permeation enhancers which irreversibly disrupt the stratum corneum [29, 30].  88 
Controversy however surrounds the use of conventional liposomes due to their large size 89 
preventing skin penetration [31, 28, 32, 33], Cevc et al., [34] demonstrated that modification 90 
of the chemical composition of the lipid bilayer so as to decease its Young’s modulus 91 
resulted in the formation of deformable liposomes.  These are able to gain access to the viable 92 
epidermis by overcoming the physical constraints imposed by the stratum corneum by 93 
diminishing the membrane elastic energy required for the liposome to deform and fit through 94 
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an aperture size smaller than their original diameter following which reforming to their 95 
original shape [35, 36, 31]. By being able to change shape and volume at minimal energetic 96 
cost, these structures may penetrate across hydrophilic pathways of intact skin [37, 36]. 97 
Deformable liposomes often include additional components designed to make the membrane 98 
more liable to deformation and these are termed edge-activators, typically including 99 
surfactants such as Tweens, bile salts and Myrj [38]. The inclusion of this extra component 100 
destabilises the vesicle bilayers by reducing the amount of energy required to expand the 101 
interface allowing the liposome to become more elastic thus increasing the flux across the 102 
skin [38-40].  103 
The primary aim of this study was to develop and characterise a deformable 104 
controlled release liposome formulation able to pass through the stratum corneum for 105 
targeting toward intracellular uptake into dermal cells. The objectives of the study were 106 
therefore to: (i) assess the impact of the edge-activator Tween 20 on liposomal formulation 107 
size; (ii) characterise resultant liposomes vesicle size, surface charge and encapsulation 108 
efficiency; (iii) quantify deformability of resultant liposomes using a deformability index 109 
(DI); (iv) assess release of EGCG; (v) assess the deformable liposome stability ; (vi) assess 110 
cellular toxicity of EGCG and (vii) assess intracellular uptake in human dermal fibroblast and 111 
keratinocyte cells. 112 
 113 
2. Materials and methods 114 
2.1 Materials 115 
Soy Phosphatidylcholine (PC) was obtained from Avanti Polar Lipids. Cholesterol 116 
(grade, ≥99%), Tween 20 and EGCG (grade ≥95%, E4143) were obtained from Sigma-117 
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Aldrich. All other reagents including methanol and chloroform were obtained from Fisher 118 
Scientific. Ultrapure water was obtained from a Milli-Q purification system (Millipore, 119 
Billerica, MA, US). Polycarbonate filter, pore size 50 nm, was obtained from Sigma-Aldrich 120 
(WHA800309). Human dermal fibroblasts (HDFa) isolated from adult skin and all cell 121 
culture reagents (Medium 106 and low serum growth supplement (LSGS) kit containing 122 
supplemented medium containing foetal bovine serum, 2 % v/v, hydrocortisone 1 µg/mL, 123 
human epidermal growth factor, 10 ng/mL, basic fibroblast growth factor, 3 ng/mL, heparin, 124 
10 µg/mL; DMEM media supplemented with 1 % L-glutamine, 10 % FBS, 1 % Penicillin 125 
Streptomycin and 0.25% amphotericin) were obtained from Life technologies (Carlsbad, 126 
California, US). Immortalized human keratinocytes (HaCat) cells were a kind gift from Dr 127 
Andrew Sanders (Cardiff China Medical Research Collaborative, Cardiff University, Henry 128 
Wellcome Building, Heath Park, Cardiff, CF14 4XN). 4,6-diamidino-2-phenylindole (DAPI) 129 
and 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate (DilC) was obtained 130 
from ThermoFisher Scientific (D1306 and D282 respectively). 131 
2.2 Methods 132 
2.2.1 Preparation of deformable liposomes with or without an edge activator  133 
Liposomes were prepared by adapting the film hydration method established by 134 
Bangham et al., (1965) [41]. Soy PC and cholesterol (16:8 µM) were dispersed in an organic 135 
solvent mixture consisting of chloroform and methanol in a 9:1 (v/v) ratio in a round 136 
bottomed flask [40, 38, 26, 42, 41]. Subsequently, the organic solvent was removed by rotary 137 
evaporation for 5 minutes at 35 °C, followed by purging with nitrogen gas. The resultant dry 138 
film residue was hydrated by the addition of 4 mL water containing edge activator (up to 10% 139 
w/w of the formulation) and 1 mg of EGCG at a temperature above the transition temperature 140 
of the phospholipid (between -7 to -15°C) [43] and vortexed for 5 minutes to form 141 
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multilamellar vesicles (MLV). The resulting particles were extruded 21 times through 100-142 
nm diameter polycarbonate membranes, using an Avanti Mini Extruder to produce 143 
unilamellar vesicles. The formed liposomes were equilibrated for 30 min above their 144 
transition temperatures (-15°C) before being subjected to further characterisation [44, 45, 43]. 145 
 146 
2.2.2 Deformable liposome characterisation  147 
The mean particle size and the polydispersity index (measurement of the level of 148 
homogeneity of particle sizes) of liposomes were measured by dynamic light scattering 149 
(DLS) using a Zetaplus (Brookhaven Instruments) following dilution with distilled water (1:4 150 
ratio) to ensure intensity adjustment. A polydispersity value of < 0.2 indicates a homogenous 151 
vesicle population, while polydispersity of > 0.3 indicates heterogeneity [46]. The particle 152 
charge was quantified as zeta potential (ζ). Zeta potential was determined by photon 153 
correlation spectroscopy using a Zetaplus (Brookhaven Instruments). The samples were 154 
diluted three-fold and assessed in triplicate.  155 
2.2.3 HPLC-UV detection of EGCG  156 
Detection of EGCG was assessed using reverse phase HPLC methodology. A Waters 157 
Alliance separation module HPLC with UV detection was utilised at an operating wavelength 158 
of 275 nm [47] with a Waters X select column (5 µm C18 4.6 x 150 mm, 186005290), with a 159 
10 μL injection volume. The mobile phase comprised of a 70:30 ratio of 0.1% TFA in water 160 
to methanol at a flow rate of 1 mL/min. Stock solutions and standard solutions of EGCG 161 
were prepared with both water and ethanol ranging from 0.5-500 µg/mL.  A final calibration 162 
curve with an R2 of 0.997 and linear equation of y = 1 x 107 ∙ x was obtained. 163 
2.2.4 Entrapment efficiency of EGCG 164 
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The entrapment efficiency of EGCG loaded deformable liposomes was determined by 165 
centrifuging samples and quantifying the EGCG in the supernatant. Samples were centrifuged 166 
at 18,000 rpm for 30 min at 4°C in an Optimatm MAX-XP ultracentrifuge to separate the 167 
incorporated drug from the free drug. The supernatant was then analysed using HPLC to 168 
determine the encapsulation efficiency of EGCG in liposomal formulations (Equation 1):  169 
! = 	$%	&	$'$% 	× 	100%	         (1) 170 
where E is the encapsulation efficiency (%), Dt is the total drug content (mg) and Ds is drug 171 
content in supernatant (mg). 172 
2.2.5 Assessment of liposomal deformability  173 
To assess the deformability of formulated liposomes, a liposome suspension (6 mL) 174 
consisting of a 16:8 micromolar ratio of PC to cholesterol formulated with up to 10% w/w of 175 
Tween 20 solution (diluted 3 fold), was passed through a polycarbonate filter of 50 nm pore 176 
size using a syringe driver (Cole Parmer, UK) set at 0.6 mL/min for 10 min. The mean 177 
particle size and the polydispersity index of liposomes were subsequently quantified by DLS, 178 
before and after filtration, to assess the ability of formulated liposomes to regain their size 179 
after having been forced through a pore size smaller than their original diameter. The 180 
deformability was quantified through the calculation of a deformability index (equation 2) 181 
[32]: 182 
, = 100	 −	./. 	× 100         (2) 183 
where D is deformability, Le is size of extruded liposomes (nm), L is size of liposomes (nm) 184 
prior to extrusion. 185 
2.2.6 Differential scanning calorimetry of EGCG and EGCG lipid blends 186 
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To assess thermal characteristics of materials including melting temperatures, phase 187 
transitions and heat capacity changes of liposomes, EGCG and ratios of lipid, surfactant and 188 
drug mixtures corresponding to that of the liposome formulation, were analysed in the solid 189 
state using a TA Instruments Q200 Thermal Analysis Differential scanning calorimetry 190 
(DSC). 3 mg of EGCG was weighed into T-Zero aluminium pans and then hermetically 191 
sealed. All experimental runs commenced at an initial temperature of 0°C, purged under 192 
nitrogen gas, with a scan rate of 10°C/min to 300°C. 193 
2.2.7 In-vitro EGCG release studies 194 
To assess the impact of inclusion of Tween 20 on EGCG from liposomal formulations, a 195 
side—by-side diffusion cell (PermeGear diffusion cell, Hellertown, USA) was maintained at 196 
35 °C.  Release was assessed over a 24 hour period from an EGCG aqueous solution (0.1 197 
mg/mL) and EGCG-loaded liposomes (final loading for liposomes formulated with 0, 2, 6 198 
and 10 % w/w Tween 20 was 0.80, 0.55, 0.17 and 0.04 mg/mL respectively). 10 mL of each 199 
formulation was placed into the donor side of the diffusion cell and release across a 50 nm 200 
membrane (Whatman®) into the receiver side containing 100 mL of dermal dissolution 201 
media with a stirrer was measured. The release media was sampled with volume replacement 202 
(0.5 mL) over 24 hours and analysed using HPLC-UV quantification. 203 
2.2.8 In-vitro drug release kinetics 204 
Several kinetic drug release mathematical models were used to assess drug release from the 205 
formulations. The best-fit to the mathematical models described below confirmed the 206 
appropriate release kinetics: 207 
Zero order model: 0%01 = 23 ∙ t        (3) 208 
where Mt/M∞ is the drug fraction released at time t and k0 is the zero-order release constant. 209 
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First order model: 0%01 = 1 − 6&789        (4) 210 
where Mt/M∞ is the drug fraction released at time t and k1 is the first-order release constant. 211 
Higuchi model: 0%01 = 2: ∙ ;8<         (5) 212 
where Mt/M∞ is the drug fraction released at time t and kH is the Higuchi constant. 213 
Korsmeyer-Peppas Model: =%= = 	>;?        (6) 214 
where Ct/C is fraction of drug released at time t, k is the release rate constant. The value of n 215 
is valuable in understanding drug release mechanisms. When n ≤ 0.45 drug release is 216 
diffusion controlled and can be referred to as ‘Fickian’ diffusion and when n > 0.89 the 217 
diffusion is indicative of erosion controlled drug release or class-II kinetics. For situations 218 
where 0.45 < n ≤ 0.89 the diffusion is a complex mixture of both processes and often termed 219 
anomalous transport. In all cases this is based on the assumption of release from a cylinder 220 
and applied to cumulative release rates < 60 % [48] 221 
Mathematical models to assess release kinetics were fit using Microsoft Excel®. Zero order, 222 
first order, Higuchi and Korsmeyer-Peppas release profiles were applied to release from drug 223 
solution and drug loaded liposome solution following which regression analysis techniques 224 
were employed to determine the probable drug-release. The release kinetic model displaying 225 
the highest r2 metric (≥0.95) was determined to be the mechanism, by which release occurred.  226 
2.2.9 Liposome stability 227 
The stability of liposomes was determined, as prepared in water, through the assessment of 228 
particle size over a 28-day period, stored in a stability cabinet maintained at 25 ± 2 °C 229 
(Firlabo, France) at a humidity of 60 % ± 5 %.  Mean particle sizes were determined on days 230 
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1, 2, 7, 14, 21 and 28 by DLS. Furthermore, the encapsulation efficiency of drug loaded 231 
liposomes was assessed over 4 weeks as detailed in section 2.2.4.  232 
2.2.10 Development of an in-vitro cellular dermal model  233 
To develop an in-vitro system to assess cellular toxicity and cellular uptake of 234 
deformable liposomes into representative human dermal tissue, two dermal cell line were 235 
examined. Human dermal fibroblasts (HDFa) were cultured in Medium 106 supplemented 236 
with low serum growth supplement. Human epidermal keratinocytes (HaCaT) cells were 237 
revived and sustained in high glucose supplemented DMEM media. Media was replaced 238 
every 3 days. At 70-80% confluency, media was discarded and cells detached using 239 
Trypsin/EDTA incubated for 5 min, prior to trypsin neutralisation with 3 mL growth media 240 
and subsequent centrifugation at 1200 rpm for 10 min and resuspension in fresh media prior 241 
to being utilized for subsequent studies  242 
2.2.11 Cellular toxicity of liposomal formulations towards HDFa and HaCat cells 243 
To determine the cytotoxicity profile of EGCG towards HDFa and HaCat cells, a 244 
(2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide (XTT) assay 245 
[49] was performed to measure cell viability after exposure to increasing concentrations of 246 
EGCG for 24 hours. Cells were seeded at a density of 50 x 103 cells per well into a 96-well 247 
plate and grown for 3 days. Thereafter, media was removed and cells were exposed to 100 µL 248 
of 0.1-100 µM EGCG and incubated for 24 hours at 37°C.  Subsequently, 25 µL of a 12.5:1 249 
(XTT: menadione) was added each well and incubated for 3 hours at 37°C prior to the 250 
absorbance being read at 450 nm. Assessment of EGCG toxicity to these cells was conducted 251 
through analysis of changes in XTT absorbance with increasing drug concentration. 252 
2.2.12 Intracellular uptake of deformable liposomes into HDFa and HaCat cells 253 
12 
 
Liposomes, both deformable and non-deformable, were formulated with the addition of 0.25 254 
mL of a 0.1 mg/mL DilC during the lipid mixing stage. Unentrapped DilC was removed by 255 
centrifuging liposomes at 18,000 g for 30 min. Coverslips were coated for 30 min with poly-256 
l-lysine (0.01 % w/v) prior to the addition of cells at a density of 50 x 103 cells per coverslip. 257 
After 24 hours, DilC loaded liposomes were diluted with 1 part of supplemented media (as 258 
clarified in materials) and were then added to the coverslips and incubated for 2 hours at 259 
37°C. 260 
Thereafter, coverslips were washed and fixed with 4 % w/v paraformaldehyde for 5 minutes 261 
at room temperature.  Subsequently, coverslips were mounted onto glass slides with the 262 
addition of a DAPI-containing mounting media. Cover slips were subsequently analysed in 263 
an upright confocal microscope (Leica SP5 TCS II MP) and visualised with a 40× oil 264 
immersion objective. Images were acquired using a helium-neon laser at 633 nm to visualise 265 
DilC and a helium–neon laser to visualise DAPI at 461 nm. 266 
2.2.13 Statistical analysis  267 
Unless otherwise stated, all results are presented as mean ± standard deviation (SD).  268 
Replicates of at least 3 were used for all studies. For multiwell plate assays replicates of 6 269 
were used for each experimental condition with the study replicated 3 times. A one-way 270 
ANOVA was used to determine any statistically significant difference between means tested 271 
(p ≤0.05). A post-hoc Tukey’s multiple comparisons test was then applied to assess 272 
differences between groups. All the calculations were carried out using Graphpad 6 273 
(GraphPad Inc., La Jolla, CA). 274 
3. Results and discussion  275 
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Emerging treatments for cancer management involve chemoprevention and chemoprotection. 276 
Current anticancer agents tend to demonstrate a poor safety profile in addition to possess a 277 
wide range of unpleasant side effects [10-12]. However, phytochemical flavonoids, such as 278 
EGCG, are increasingly being investigated for their chemoprevention properties [13-15].  279 
EGCG is a flavonoid found in green tea that possesses cytotoxic effects in cancerous skin 280 
cells and thus may be a potentially viable candidate as a pharmacological anti-cancer agent 281 
[16], given that it has been observed to induce apoptosis in cancer cells without affecting 282 
normal cells [50, 17], in addition to the modulating expression of a number of genes involved 283 
in cell proliferation, cell-cell contact and cell-matrix interactions [51].  284 
However, the penetration of drugs across the skin is significantly hindered by the skin’s 285 
inherent barrier properties [25].  The use of deformable liposomes to aid dermal cellular  286 
penetrability and uptake may be advantageous in the targeting of neoplastic agents to deeper 287 
skin cellular layers when compared to conventional liposomes which may not be able to 288 
penetrate through the narrow pore of the stratum corneum [39].  289 
This focus of this study was to develop EGCG loaded slow release deformable liposomes. 290 
EGCG liposomes were formulated with PC and cholesterol with the inclusion of Tween 20 as 291 
a edge-activator with incorporation of up to 10 % w/w. Liposomal characteristics including 292 
liposome size, charge, encapsulation efficiency, DI, release profile, stability, ceulluar toxicity 293 
and uptake were was assessed. 294 
3.1 Liposome characterisation 295 
The impact of the inclusion of Tween 20 within the liposomal formulation on 296 
liposome characteristics were observed. As the surfactant loading in the bilayer of ‘empty’ 297 
liposomes increased, liposome diameter decreased from 206 ± 24 nm for liposomes 298 
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formulated with no surfactant to 102 ± 11 nm for liposomes formulated with 10 % w/w 299 
Tween 20 (Figure 1A). As the surfactant loading in the bilayer of EGCG loaded liposomes 300 
increased, liposome diameter decreased, from 258 ± 17 nm for liposomes formulated with no 301 
surfactant compared with 105 ± 13 nm for liposomes formulated with 10 % w/w Tween 20 302 
(Figure 1B). The decrease in size was statistically significant (p ≤ 0.05) for ‘empty’ and 303 
EGCG loaded liposomes formulated with no surfactant compared with liposomes loaded with 304 
2, 6 and 10 % w/w Tween 20.  305 
[Figure 1 near here] 306 
The inclusion of surfactants into liposome formulations have previously been demonstrated 307 
to decrease liposome size when compared to liposomes formulated in the absence of 308 
surfactant [26, 32]. This may be as a result of a destabilising effect imparted by the surfactant 309 
on the bilayer [52], which results in a greater interaction of the phospholipid bilayer with the 310 
aqueous phase.  A consequence of this would then be the overall formation of liposomes with 311 
a smaller diameter giving a greater surface area in contact with the aqueous phase.  The 312 
inclusion of surfactant has been previously reported to decrease liposome size in comparison 313 
to conventional liposomes. A study formulating liposomes with Phospholipon® 90 G and 314 
both Tween 80 and Span 80 reported a size reduction from 207 nm to 139 nm following 315 
inclusion of the surfactants [32]. 316 
A liposome preparation which is homogenous in size is important as final liposome 317 
size will partly determine the level of tissue distribution in-vivo in addition to influencing 318 
drug release kinetics. A polydispersity of up to 0.3 is considered homogenous [53, 32, 54]. As 319 
the loading of surfactant increased, the polydispersity of the liposomal formulation did not 320 
significantly change for ‘empty’ liposomes (Figure 1a) whilst a significant decrease was 321 
observed for those loaded with EGCG (P ≤ 0.0001) from 0.3 to 0.2 (Figure 1b). Therefore, 322 
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the inclusion of Tween 20 within the liposome formulation appeared to improve homogeneity 323 
(although liposome production method may also impact this quality). 324 
The magnitude of the zeta potential (ζ) indicates the degree of electrostatic repulsion 325 
between adjacent, similarly charged particles in a dispersion. Thus, it is a fundamental 326 
parameter thought to affect stability of liposomal formulations. All formulated liposomes 327 
demonstrated a near neutral charge (Table 1). A neutral liposomal surface charge is important 328 
to avoid skin irritation [55] however, this may subsequently lead to particle flocculation due 329 
to a lack of electrostatic repulsion between liposomes causing them to cluster [56].  330 
[Table 1 near here] 331 
In liposomes formulated with EGCG, as Tween 20 loading increased, a statistical 332 
significant decrease in EGCG entrapment was observed, (P ≤ 0.0001), from 80.0 ± 3.0 % 333 
when no surfactant is present to 4.3 ± 3.0 % with a 10 % w/w loading of surfactant (Figure 2). 334 
This decrease in EGCG loading may be related to the difference in the molecular weight of 335 
EGCG and Tween 20. Tween 20, with larger molecular weight of 1227.54 g/mol compared to 336 
that of EGCG (386.65 g/mol), may be assumed to be better poised to displace EGCG from 337 
the bilayer. Further, the hydrophobic tail of Tween 20 would have a high affinity to the 338 
chains in PC disrupting the liposome structure as well as displacing EGCG from the bilayer 339 
[57-59]. Furthermore, Tween 20 is known to enhance the solubility of drugs and therefore, as 340 
not all would be entrapped within the bilayer, this may allow increased EGCG solubilisation 341 
within the liposomal rehydration media [60]. It is also possible that the coexistence of 342 
vesicles and mixed micelles at high surfactant concentrations [61] may have reduced the 343 
compound entrapment in mixed micelles.  344 
[Figure 2 near here] 345 
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The degree of deformability of each formulation was determined by extrusion through 346 
a polycarbonate filter with a pore size of 50 nm. The mean particle size and the polydispersity 347 
index of liposomes was quantified before and after filtration to assess liposome ability to 348 
regain size after having being forced through a pore size smaller than their original diameter. 349 
The DI is defined as the degree the liposomes deformed; the greater the degree of 350 
deformation the less elastic the liposomes are as they were unable to regain their previous 351 
larger size. The DI following extrusion decreased with statistical significance (P ≤ 0.0001) as 352 
surfactant loading increased in ‘empty’ liposomes, from 71 ± 6 for liposomes formulated with 353 
no surfactant compared with 26 ± 3 % for liposomes formulated with 10 % w/w Tween 20 354 
respectively. EGCG liposomes formulated with Tween 20 demonstrated a statistically 355 
significant decrease (P ≤ 0.0001) in DI from 74 ± 8 for liposomes formulated with no 356 
surfactant compared with 37 ± 7 for liposomes formulated with 10 % w/w Tween 20 (Figure 357 
3). These observations imply the liposomes were displaying elastic properties as they could 358 
deform in order to pass through an opening smaller than its own diameter whilst, to a certain 359 
degree regaining its size. It is important to address the initial size of liposome. Those 360 
formulated with Tween 20 were of a smaller diameter thus would require less deformation to 361 
fit through the pores. However, the pore size was smaller than liposome diameter in all cases 362 
and the DI equation requires the ratio of pre to post extrusion size. Additionally, the presence 363 
of EGCG in the liposome formulation did not appear to affect the DI compared with 364 
liposomes formulated without. A study formulating liposomes with Phospholipon® 90 G and 365 
both Tween 80 and Span 80 saw a size reduction observed surfactant to decrease the DI from 366 
51 ± 4 to 17 ± 5 [32]. 367 
[Figure 3 near here] 368 
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Liposomes formulated with surfactant can deform as the surfactant has a propensity 369 
for highly curved structures (e.g. micelles and liposomes), thus diminishing the energy 370 
required for particle deformation. The surfactant is able to diminish the energy required for 371 
particle deformation and accommodate particle shape changes of the liposomes under stress 372 
[62]. These surfactants may have interacted with the PC with strong affinity but in reversible 373 
mode. The reversible binding mode might have provided the deformability upon physical 374 
stress [38]. 375 
For liposomes to deform, a source of energy is required [63-65]. In our 376 
systems, ’energy’ was supplied to this system in the form of pressure as a result of the action 377 
of the syringe driver. The larger the concentration of surfactant included within the 378 
formulation, the greater the energy the liposome as a whole is be able to retain [65]. It is 379 
postulated that this energy is used to reorientate the lipid bilayer structure, and since all 380 
systems tend toward the lowest state of free energy, the energy stored in this structure will be 381 
expelled once the liposome has passed through the pore and there is no longer any pressure 382 
forcing the bilayer to remain in an ‘unnatural state’ [35, 36, 66]. This energy can then be 383 
expended into reforming the liposome. Some energy will be lost during passage as heat or 384 
non-plastic deformation, therefore it was not possible to attain a DI of 0 %.  385 
The energy used to alter the bilayer of a liposome containing no surfactant does not benefit 386 
from the extra ‘storage space’ of a surfactant, thus energy may be expended to rupture the 387 
membrane causing liposome size to decrease [65]. Despite the potential for excess energy in 388 
liposomes formulated with Tween 20, liposomes were not able to fully regain their pre-389 
extrusion size. Some energy will always be lost in the friction of the particles moving through 390 
the pores as heat [67]. An increase in surfactant loading may bring the liposomes closer to 391 
100% reformation [65]. Further, liposomes unable to fit through the pores or lipid aggregates 392 
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from ruptured liposomes may cause blockages. This may lead to an increase in pressure in the 393 
vessel causing more turbulence leading to the rupture and non-uniform reformation of 394 
liposomes. Additionally, in-vivo, liposomes would be expected to move across the skin 395 
following an osmotic transepidermal gradient as has been reported in many similar studies 396 
concerning the dermal and transdermal delivery of drug [64, 39, 65, 32]. Such lipid carriers 397 
are miscible with the epidermal lipids present within the barrier of the stratum corneum thus 398 
would be able to penetrate into deeper layers of the skin [68-70]. Furthermore, the skin is 399 
warmer than room temp (35 °C compared to 20 °C). Temperature governs the energy term of 400 
enthalpy therefore the liposomes would have more energy to be even more flexible and cross 401 
the stratum corneum. 402 
3.2 Differential scanning calorimetry investigations of EGCG and EGCG lipid blends 403 
Differential scanning calorimetry (DSC) has been widely used in understanding the 404 
thermal characteristics of materials where an insight into a range of thermal properties 405 
including melting temperatures, phase transitions and heat capacity changes can be obtained.  406 
It has been observed that drugs with melting point of < 200 °C are better poised to cross the 407 
SC [71, 24], therefore observing the effect of formulation parameters on the melting point 408 
would aid formulation development. The glass transition temperature (Tc) of EGCG was 409 
identified at 220 °C (peak c) and the melting point (Tm) of EGCG was at 245 °C (peak d) 410 
(Figure 4) and concurred with those reported by Cho et al (2008) where the Tm of GCG (an 411 
epimer of EGCG) was at 223 °C, the Tc of EGCG was at 235 °C and the Tm of EGCG was at 412 
246 °C. Cho et al also observed a peak at 97 °C and determined it to be the conversion 413 
temperature of EGCG into GCG. Therefore, the first two troughs (peak a and b) observed in 414 
the scan may be representative of the epimer GCG [72]. Differences between reported values 415 
and those observed here may be due to differences in EGCG sample purity.    416 
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[Figure 4 near here] 417 
The DSC of the lipid (PC and cholesterol) and Tween 20 blend observed the Tm of 418 
this mixture to be 172 °C (Figure 5A). There is also a smaller absorption peak at 208°C 419 
which would be attributed to one of the liposomal components. Upon addition of EGCG to 420 
this mixture, comparison to the aforementioned DSC data observed the melting point shifted 421 
to 191 °C (Figure 5B). Furthermore the Tm of EGCG decreased from 242°C to 191°C 422 
illustrating that the surfactant loaded liposomes could decrease the Tm of EGCG thus 423 
potentially improving partitioning across a membrane [73-75]. Furthermore, the addition of 424 
EGCG caused the peak at 208°C to either disappear or shift into the main peak observed at 425 
191°C. 426 
[Figure 5 near here] 427 
3.3 EGCG release studies from liposomal formulations  428 
The release of EGCG from solution and liposomal formulations was studied over a 24-hour 429 
period (Figure 6). Liposomes appeared to retard the release of EGCG in comparison to 430 
release across the membrane from EGCG in solution. Furthermore, with increasing the 431 
loading of Tween 20 within liposomal formulations (0 to 10 % w/w), EGCG release 432 
increased from 14 ± 1 % at 24 hours for 0 % w/w Tween 20, to 94 ± 5 % at 24 hours for 10 % 433 
w/w Tween 20. The cumulative percentage released after 24 hours was significant between 434 
the solution and liposomes loaded with 0%, 2%, and 6% w/w of Tween 20 (P ≤ 0.0001). The 435 
inclusion of surfactant enables an increase in drug solubility of poorly soluble compounds 436 
thus explaining the increase in drug release at higher loadings of surfactant. Such properties 437 
are already exploited to improve the oral delivery release profiles of poorly soluble 438 
compounds in self-emulsifying drug delivery systems with four drug products [76, 77], 439 
Sandimmune® and Sandimmun Neoral® (cyclosporin A), Norvir® (ritonavir), and 440 
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Fortovase® (saquinavir) on the pharmaceutical market [76]. It is worth noting that as 441 
surfactant loading increased, EGCG entrapment decreased thus a lower concentration 442 
gradient would be observed. This did not appear to retard EGCG release. 443 
[Figure 6 near here] 444 
An increased rate of release was observed from the EGCG solution compared with 445 
liposome formulations over the 24 hours observed (Table 2). Further, as the loading of 446 
surfactant increased, the rate of EGCG release increased (from 0.034 ± 0.013 to 0.993 ± 447 
1.013 for liposomes loaded with 0 % and 10 % of Tween 20 respectively based on the 448 
Korsmeyer-Peppas model). Thus, surfactant appears to increase drug release/encourage 449 
liposome breakdown, particularly at 10 % w/w where the rate was 10 fold greater than that at 450 
6% w/w. The surfactant would increase drug solubility thus explaining why an increase in 451 
drug release is observed at higher loadings of surfactant. The inclusion of surfactant 452 
destabilizes the vesicle bilayers by reducing the amount of work required to expand the 453 
interface allowing the liposome to become more flexible [40, 38, 39] and move through the 454 
membrane. Additionally, it has been suggested that the mechanism of the in-vitro release 455 
seems to be the formation of transient pores in the lipid bilayer, through which drugs are 456 
released to the extra-liposomal medium (Wang, Wang et al. 2016).  457 
[Table 2 near here] 458 
Based on the values of the determination coefficient (R2), as well as AIC values 459 
(Akaike Information Criterion), the model that best describes EGCG release from all 460 
liposomal formulations is Korsmeyer-Peppas model (highest R2 and lowest AIC). The 461 
diffusion release exponent value revealed a range of release mechanisms for each formulation. 462 
Liposomes formulated with 0%, 6 % and 10% w/w Tween 20 had an exponent value of 0.839 463 
± 0.072, 0.836 ± 0.116 and 0.722 ± 0.247 respectively indicating the release is a complex 464 
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mixture of the diffusion (flux due to molecular diffusion and the concentration gradient) and 465 
erosion controlled drug release or class-II kinetics (diffusion not based on concentration 466 
gradient) processes and often termed anomalous transport [78]. Liposomes formulated with 2 467 
% w/w Tween 20 observed an exponent value of 0.913 ± 0.186 indicative of erosion 468 
controlled drug release or class-II kinetics [48]. 469 
3.4 Stability of EGCG loaded deformable liposomes 470 
The impact of long-term storage of EGCG-loaded liposomes formulated with 2 % 471 
w/w Tween 20 was assessed during storage in stability cabinets maintained at 25 ± 2 °C 472 
(Firlabo, France) at a humidity of 60 % ± 5 %. Liposomes formulated with 2% w/w Tween 473 
were selected in this study as it had the highest EGCG entrapment compared with the higher 474 
loadings of surfactant thus will be taken forward for cell uptake studies. The impact of this 475 
storage on size (Figure 7) and encapsulation efficiency (Figure 8) was assessed. EGCG 476 
loaded liposomes formulated with and without surfactant maintained a consistent size over 477 
time (Figure 7) with no statistically significant difference in size during the storage period. 478 
Previous reports have highlighted that aggregation is common upon liposomal formulation 479 
storage, and results in vesicle size growth [79] particularly, though not always, with neutral 480 
liposomes [56]. However, the inclusion of Tween 20 into the deformable liposomes may have 481 
prevented this phenomenon and may be a result of surfactant destabilising the lipid bilayer 482 
and reducing the energy required to expand the interface, thus allowing maintenance of 483 
smaller structures. It appears the inclusion of surfactant prevents this phenomenon which 484 
correlates with similar studies [80].  485 
[Figure 7 and 8 near here] 486 
Furthermore, encapsulation efficiency showed a trend of decreasing loading from 43 ± 7 % to 487 
42 ± 12 %, 39 ± 9 %, 30 ± 11 % to 30 ± 6 %, for liposomes formulated with 2 % w/w Tween 488 
22 
 
20 (Figure 8). Tween 20 is able to increase compound solubility, therefore, this may allow 489 
EGCG to solubilise within the liposomal media [60] and leach out over time.  490 
3.5 Cellular toxicity of liposomal formulation towards HDFa and HaCat cells 491 
Whilst topical formulations are applied directly into the skin, various connective layers 492 
making up the skin are important for drug delivery. The skin primarily consists of the 493 
epidermis, dermis and subcutaneous layers and each layer has a unique combination of cells, 494 
connective tissue, components and functions. Skin cancers develop in the upper layers of the 495 
skin spanning the dermal and epidermal layer, and any formulation system should consider 496 
the impact of formulation systems on these tissue layers for the delivery of drugs.  497 
In order to assess cellular toxicity of EGCG to these cells, we adopted two in-vitro cell 498 
culture systems, namely human keratinocyte and human fibroblast cells. To determine the 499 
cellular viability cytotoxicity of EGCG towards HDFa and HaCat cells, an XTT assay was 500 
performed to measure cell death after exposure of cells to different concentrations of drug for 501 
24 hours (Figure 9). 502 
[Figure 9 near here] 503 
As the concentration of EGCG was increased from 0.1 to 100 µM, HDFa cell viability 504 
decreased (Figure 9A) with statistical significance (P ≤ 0.0001). This may be due to toxicity 505 
or death of damaged cells in which EGCG induced apoptosis [81, 82]. Whilst limited data 506 
exists on the cytotoxicity of EGCG towards dermal tissues, a study observing growth 507 
inhibition in multiple cell lines, observed that EGCG at 40 μM had little or no inhibitory 508 
effect on the growth of WI38 cells, normal human fibroblast cells [83]. Cell viability was 509 
maintained across the concentration range of 0.1–100 µM on HaCat cells (Figure 9B). No 510 
statistically significant difference was observed in cell viability. Furthermore, EGCG has 511 
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been reported to impart protective effects in HaCat cells exposed to external stressors 512 
including UVA and UVB radiation [84, 85]. Whilst some of our formulations exceeded this 513 
concentration of EGCG as a whole, the retarded release profile of the liposomes would be 514 
expected to result in an overall lower temporal concentration profile exposure to these cells, 515 
significantly below 100 µM. 516 
3.6 Cellular liposomal uptake assay into HDFa and HaCat cells 517 
A primary goal for our studies was to demonstrate uptake of deformable liposomes 518 
loaded with EGCG into a cell culture skin model. EGCG loaded liposomes were incubated 519 
with both HaCat (Figure 10) and HDFa (Figure 11) cells to assess the cellular uptake of these 520 
formulations. Liposomes formulated with 2% w/w Tween 20 were selected, a result of the 521 
highest EGCG entrapment compared with the other surfactant loadings. Fluorescently 522 
labelled liposomes loaded with EGCG incubated for 2-hours with both HaCat and HDFa cells 523 
seeded onto collagen-coated coverslips and the cellular localisation of these liposomes was 524 
determined using confocal microscopy.  Following a 2-hour incubation with the cells, 525 
intracellular localisation of labelled liposomes were clearly evident, confirming the 526 
successful uptake into both HaCat and HDFa cells.  527 
[Figure 10 and 11 near here] 528 
  Extraneous particle cell uptake is dependent upon influences such as particle size, 529 
charge, affinity etc. [86-88]. There are four proposed methods of liposome uptake into cells: 530 
stable adsorption, endocytosis, fusion of the lipid bilayer with the cell plasma membrane and 531 
lipid transfer [43, 89]. It is unclear which of these, or another process, occurred in this study, 532 
however, these methods of uptake are not mutually exclusive and any combination may occur 533 
in a given experimental circumstance [43]. The interaction of nanoparticles with cell 534 
membrane seems to be most affected by particle surface charge. The cell membrane surface 535 
24 
 
is dominated by negatively charged sulphated proteoglycans molecules (vital in cellular 536 
proliferation and migration) [90, 91]. These molecules are associated with 537 
glycosaminoglycan side chains (heparan, dermatan, keratan or chondrotine sulfates) which 538 
are anionic, and interaction between proteoglycans and liposomes, if positively charged, tend 539 
to be largely ionic [92]. The liposomes applied to the cells in this study had a ζ of 4 ± 1 540 
suggesting an ionic interaction may have occurred. A study applying cationic liposomes 541 
formulated with the cationic lipids Lipofectin, Tfx-50, and Lipofectamine in oligonucleotide 542 
delivery to HaCat cells observed liposome uptake within 24 hours [93]. Furthermore, 543 
research developing chemotherapy against malignant melanoma using mouse B16 melanoma 544 
cells as well as Normal Human Dermal Fibroblasts observed a greater uptake of cationic 545 
liposomes by cells in the injection site compared with neutral liposomes due to the 546 
electrostatic interaction with the negative-charged phospholipid membrane of cells [94].  547 
It should be noted that the confocal microscopy studies demonstrated the possibility of the 548 
delivery of deformable liposomes to relevant dermal tissues using in-vitro cell culture 549 
techniques.  However, the application of such formulations could also be assessed using ex-550 
vivo human or animal dermal tissues. The ultimate aim of this delivery system was to 551 
improve dermal cell uptake and delivery a controlled release of active agent, thus from a 552 
regulatory perspective, pharmacokinetic data is not required as drug is not intended to reach 553 
the blood stream [95].  554 
This study did not address skin penetration. The liposomes formulation recommended to take 555 
into further studies would be that loaded with 2% w/w Tween 20. In order to ascertain the 556 
extent of carrier and drug permeation a skin strip test may be appropriate [70]. This involves 557 
the use of an adhesive tape to strip the skin layer by layer and quantifying lipid and drug on 558 
each layer[96]. Further, whilst the most appropriate animal model for human skin is the 559 
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porcine skin tissue, sample-to-sample variability in addition to differences in the lipid dermal 560 
matrices often results in an altered permeability profile limiting the wider human translational 561 
goals [97-99]. The use of skin tissue samples would also help determine whether intact 562 
liposomes deliver EGCG to dermal cells or if EGCG delivery is as a result of liposomes 563 
being mixed with lipids present in the stratum corneum. 564 
4. Conclusion  565 
Skin cancer is emerging as an increasing public health problem particularly in 566 
developed countries. Current treatments include surgery to remove the tumour as well as 567 
topical formulations. Such treatments may not be suitable for all patients as they are 568 
associated with an unpleasant aesthetic profile as well as side effects. A nanoparticle delivery 569 
system such as deformable liposomes applied topically for the direct dermal delivery of 570 
compounds would be valuable in carrying compounds across the stratum corneum at a 571 
controlled rate whilst limiting side effects. The use of naturally occurring compounds such as 572 
EGCG have been found to be successful as chemopreventative and chemoprotective agents. 573 
However, formulation of such compounds has been limited in success due to a limited 574 
bioavailability of promising agents and inefficient delivery systems. We developed a novel 575 
deformable liposome formulation loaded with EGCG and systemically investigated the 576 
loading, uptake and in-vitro release of EGCG from these nanoparticles. This study has found 577 
deformable liposomes could be valuable in targeted delivery whilst offering controlled 578 
release of the compound [13, 100]. We have demonstrated that as the amount of Tween 20 in 579 
the liposomal bilayer is increased, liposome size decreased and elasticity increased. As the 580 
loading of Tween 20 in the liposome was increased the EGCG encapsulation decreased. This 581 
may have been due to Tween 20 competing for space within the bilayer or due to Tween 20 582 
increasing the solubilisation capacity of EGCG. Additionally EGCG release from liposomes 583 
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found that the liposomes were able to modify the release of drug with complete release 584 
observed within 24 hours. Further, our studies demonstrated these liposomes were capable of 585 
uptake into epidermal keratinocytes and dermal fibroblasts within 2 hours.  This present study 586 
demonstrates liposomes formulated with Tween 20 are useful in the development of a 587 
controlled release topical formulation for dermal delivery crucial in improving patient 588 
compliance thus skin cancer treatment outcomes.  589 
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Table 1: Zeta potential of liposomal formulations formulated in the absence and presence of 848 
up to 10% w/w of Tween 20 849 
Surfactant 
loading (% w/w) 
Zeta potential (mV)  
‘empty’ 
liposomes 
EGCG loaded 
liposomes 
0 5.03 ± 1.03 2.41 ± 1.08 
2 4.67 ± 1.08 3. 67 ± 0.91 
6 3.71 ± 0.90 -0.99 ± 1.01 
10 -2.79 ± 0.20 -1.90 ± 0.88 
Results are presented as the mean ± standard deviation (n=3) 850 
 851 
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Table 2: In-vitro SA release kinetics models 852 
Kinetic 
model 
Parameter Tween 20 Loading (% w/w)_ 
0  2  6  10  
0 (k0) ×10-2 
mg • min-1 
1.01 ± 0.05 1.18 ± 0.01 2.75 ± 0.05 7.77 ± 0.02 
R2 0.95 ± 0.02 0.99 ± 0.01 0.93 ± 0.07 0.72 ± 0.30 
AIC 28.59 ± 4.44 18.82 ± 2.96 57.24 ± 14.21 98.21 ± 25.32 
1st (k1) × 10-4 
min-1 
1.07 ± 0.05 1.27 ± 0.13 3.32 ± 0.58 15.04 ± 3.11 
R2 0.96 ± 0.02 0.986 ± 0.01 0.96 ± 0.04 0.94 ± 0.06 
AIC 25.68 ± 4.40 18.132 ± 6.83 54.03 ± 6.46 4.56 ± 17.86 
Higuchi  kH 0.26 ± 0.01 0.294 ± 0.03 0.71 ± 0.09 2.12 ± 0.14 
R2 0.83 ± 0.04 0.7513 ± 0.03 0.81 ± 0.05 0.86 ± 0.10 
AIC 47.40 ± 5.92 58.783 ± 4.90 77.32 ± 9.63 99.05 ± 13.13 
Korsmeyer-
Peppas 
kKP 0.03 ± 0.01 0.059 ± 0.08 0.09 ± 0.06 0.99 ± 1.01 
N 0.84 ± 0.07 0.913 ± 0.19 0.84 ± 0.12 0.72 ± 0.25 
R2 0.99 ± 0.01 0.991 ± 0.01 0.99 ± 0.01 0.96 ± 0.03 
AIC  11.26 ± 3.00 27.163 ± 22.24 49.82 ± 8.49 82.76 ± 9.81 
R2, coefficient of determination; AIC, Akaike Information Criterion; F is the fraction of drug released at time t; k0 is the zero-order release 853 
constant; k1 is the first-order release constant; kH is the Higuchi release constant; kKP is the release constant incorporating structural and 854 
geometric characteristics of the drug- dosage form; n is diffusion release exponent.  855 
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List of figures 856 
Fig. 1 Liposome size distribution and polydispersity of ‘empty’ and EGCG loaded liposomes 857 
Liposome size distribution and polydispersity, determined by DLS, comparing (A) ‘empty’ 858 
and (B) EGCG loaded formulations with Tween 20 (0-10 % w/w). Liposomes were prepared 859 
by the dry film hydration method and EGCG added during the lipid mixing stage. Data 860 
represents mean ± SD. n=3 independent batches. **** indicates statistical comparison 861 
between the size of liposome formulations with a P ≤ 0.0001. # # indicates statistical 862 
comparison between the polydispersity of liposome formulations with a P ≤ 0.01.  863 
Fig. 2 Entrapment efficiency of EGCG in liposomes formulated with 0-10% w/w Tween 20 864 
Entrapment efficiency (%) of EGCG in liposomes formulated with varying amounts of 865 
Tween 20 (0-10% w/w) Data represents mean ± SD. n=3 independent batches. **** indicates 866 
statistical comparison between the entrapment efficiency of liposome formulations with a P ≤ 867 
0.0001. 868 
Fig. 3 Deformability index for ‘empty’ and EGCG loaded liposomes 869 
Deformability index following extrusion through 50 nm membranes for ‘empty’ and EGCG 870 
loaded liposomes with increasing surfactant loading up to a maximum of 10% w/w. 871 
Liposomes were prepared adapting the dry film method adding the surfactant and adding 872 
EGCG during the lipid mixing stage. The preparation was vortexed and then extruded though 873 
the membranes. Data represents mean ± SD. n=3 independent batches. **** indicates 874 
statistical comparison between the DI of liposome formulations with a P ≤ 0.0001. 875 
Fig. 4 Differential scanning calorimetry scan of EGCG 876 
All experimental runs commenced at an initial temperature of 0 °C with a scan rate of 10 877 
°C/min to 300 °C. Peak a and b are related to the epimer of EGCG, GCG. Peak c represents 878 
the glass transition temperature (Tc) of EGCG was at 220 °C and the melting point (Tm) of 879 
EGCG was at 245 °C. 880 
Fig. 5 Differential scanning calorimetry analysis scans of PC, cholesterol and Tween 20 and 881 
EGCG blends 882 
DSC analysis scans of (A) PC, cholesterol and Tween 20 blend and (B) PC, cholesterol, 883 
Tween 20 and EGCG blend. The Tm of the lipid mixture is 172 °C, and upon addition of 884 
EGCG, the Tm was 191 °C. All experimental runs started at an initial temperature of 0 °C, 885 
purged under nitrogen gas, with a scan rate of 10 °C/min to 300 °C. 886 
Fig. 6 In-vitro percentage EGCG cumulative release profiles from solution and liposomal 887 
formulations 888 
EGCG release profiles from solution and liposomes formulated with 0, 2, 6 or 10 % w/w 889 
Tween 20 over 24 hours.  Liposomes were prepared adapting the dry film method adding the 890 
surfactant and EGCG during the lipid mixing stage. A diffusion cell dialysis system was used 891 
to evaluate in-vitro drug release. Data represents mean ± SD. n=3 independent batches. **** 892 
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indicates statistical comparison between the EGCG release of liposome formulations with a P 893 
≤ 0.0001. 894 
Fig. 7 Stability of EGCG loaded liposomes as determined by size 895 
Size of EGCG loaded liposomes formulated with 0-10% w/w Tween 20, using DLS, 896 
formulated with up to 10% w/w Tween 20 measured on various days (1, 7, 14, 21 and 28). 897 
Data represents mean ± SD. n=6 independent batches.  898 
Fig. 8 Liposome encapsulation efficiency for EGCG 899 
Liposome encapsulation efficiency for EGCG in liposomes formulated with 2 % w/w Tween 900 
20 liposomes over 28 days. Liposomes were prepared adapting the dry film method adding 901 
the surfactant and drug during the lipid mixing stage. The preparation was then washed via 902 
centrifugation. The quantity of EGCG in supernatant over 28 days was then analysed by 903 
HPLC coupled with UV detection to assess liposome stability. Data represents mean ± SD. 904 
n=6 independent batches. 905 
Fig. 9 Cellular toxicity of EGCG  906 
HDFa (A) and HaCat (B) cells were grown on a 96-well plate at a density of 50 x 103 cells 907 
per well and exposed to various concentrations of EGCG (0.01-100 µM) for 24 hours.  908 
Thereafter 25 µL of a 12.5:1 parts mixture of XTT to menadione was added each well. Plates 909 
were incubated for 3 hours at 37°C and the absorbance read at 450 nm. Data is reported as 910 
mean ±SD with 6 replicates per compound in at 3 independent experiments. ****, ***, **, * 911 
indicates statistical comparison between the entrapment efficiency of liposome formulations 912 
with a P ≤ 0.0001, 0.001, 0.01 and 0.05 respectively.  913 
Fig. 10 Localisation of DilC labelled liposomes loaded with EGCG and 2% w/w Tween 20 in 914 
HaCat cells 915 
Cells were grown on the coverslips for 2 days. Cell nuclei were visualised using (A) DAPI 916 
(Blue). Liposomes were formulated with DilC for visualisation (B) (yellow). Liposome 917 
localisation within the cell is shown in the merged image (C). 918 
Fig. 11 Localisation of DilC labelled liposomes loaded with EGCG and 2% w/w Tween 20 in 919 
HDFa cells 920 
Cells were grown on the coverslips for 2 days. Cell nuclei were visualised using (A) DAPI 921 
(Blue). Liposomes were formulated with DilC for visualisation (B) (yellow). Liposome 922 
localisation within the cell is shown in the merged image (C).  923 
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